ENDRA Life Sciences Inc.

ENDRA Life Sciences reported improved financial results for 2025, with a net loss of $7.0 million compared to $11.5 million in 2024, driven primarily by a significant reduction in operating expenses to $5.8 million from $10.8 million. This expense reduction resulted from actions taken in 2024 to streamline operations and focus resources on core development priorities, though the 2024 figure included a $2.3 million non-cash inventory valuation charge related to the strategic shift of the TAEUS Liver device. The company's clinical progress was highlighted through multiple feasibility studies demonstrating TAEUS Liver's strong correlation with MRI-PDFF (the gold standard) and robust intra-user repeatability, positioning the device as a potential tool for pharmaceutical trials and routine clinical practice for steatotic liver disease. Management commentary emphasized confidence in the long-term potential of TAEUS technology while acknowledging the strategic alternatives review process initiated by the Board on March 25, 2026. The company's financial position shows $762,000 in cash and cash equivalents as of December 31, 2025, supplemented by $2.0 million in Digital Assets as part of its capital management strategy, with total stockholders' equity of $2.26 million.